Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

María E. Figueroa, Omar Abdel‐Wahab, Chao Lü et al. · Cancer Cell · 2010 · 2.7K citations · Full text

Hematological Malignancy, Somatic Variant, Hypermethylation Phenotype +10

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.6K citations

Mixed-phenotype Acute Leukemia, Pathology, Acute Leukemia +18

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

<i>DNMT3A</i> Mutations in Acute Myeloid Leukemia

Timothy J. Ley, Li Ding, Matthew J. Walter et al. · New England Journal of Medicine · 2010 · 2K citations · Full text

Mutation in <i>TET2</i> in Myeloid Cancers

François Delhommeau, Sabrina Dupont, Véronique Della Valle et al. · New England Journal of Medicine · 2009 · 1.7K citations · Full text